~~<i id='FC70563CB4'><strike id='FC70563CB4'><tt id='FC70563CB4'><pre id='FC70563CB4'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

entertainment

fashion

author：leisure time 2025-10-01 23:02:16 - browse：6

Roche’s announcement Monday that it would pay $310 million for rights to a hypertension treatment, zilebesiran, invented by the biotech firm Alnylam is evidence of a renewed interest on the part of large pharmaceutical companies for treatments for cardiovascular disease.

If things go well, Roche could pay Alnylam up to $2.8 billion in total.

Heart drugs were once the most lucrative category of pharmaceuticals, but they have been eclipsed by treatments for cancer and other diseases as drug firms have struggled to one-up existing treatments for high blood pressure and high cholesterol that are now available as cheap generics.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： Resistance to opioid

Wikipedia

hotspot

knowledge

hotspot

entertainment

focus

KristofferTripplaar/APEventually,theluckiestcompaniesgettodealwithaveryparticularproblem:whattodowhe

WSS

Congress might make insulin pumps more accessible to the blind

Change Healthcare payments predicted restored March 15

Study gives hint on South Asians’ higher risk of cardiovascular disease

In his State of the Union, Biden takes clear aim at 'Big Pharma'

A deep dive into Applied Therapeutics’ data, and questions on Cassava

Readout Newsletter: Amylyx, Aurinia, and IQVIA

entertainment

fashion

Wikipedia

Trump demands the U.S. pay no more for drugs than other countries … again

Former medical device CEO who sold dummy, plastic parts convicted of fraud

23andMe had bad news about my health. I wish a person had delivered it

Having children helps parents live longer, especially after age 80

Supreme Court strikes down use of affirmative action

Having children helps parents live longer, especially after age 80

Sports medicine is finally prioritizing gender equality

Ebola vaccine can save some who are already sick, per new study

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Here’s what’s in the FDA plan to include pregnant women in clinical trials

hotspot

Readout Newsletter: Amylyx, Aurinia, and IQVIA

NEJM study link tiny plastics in blood vessels to heart problems

Just how do doctors, lawmakers, and the public define abortion?

Long Covid research funding gets a major boost from NIH

AMAs digital advisors table RPM coding reform proposal, again

Resistance to opioid

knowledge

hotspot

entertainment

focus